Valensa teams with Neptune
This article was originally published in The Tan Sheet
Valensa International extends its patented eye health formulas by adding Neptune Technologies and Bioressources' Neptune Krill Oil to its condition-specific dietary supplements. The Orlando, Fla., firm announced Oct. 6 it signed an exclusive, worldwide license with Neptune. It plans to launch the new eye and joint health formulas in the first quarter of 2010. Valensa is evaluating the efficacy of the new formulas in clinical trials now
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.